Matts Kågedal

682 total citations
38 papers, 517 citations indexed

About

Matts Kågedal is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Matts Kågedal has authored 38 papers receiving a total of 517 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Radiology, Nuclear Medicine and Imaging, 12 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Matts Kågedal's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Statistical Methods in Clinical Trials (5 papers). Matts Kågedal is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Statistical Methods in Clinical Trials (5 papers). Matts Kågedal collaborates with scholars based in Sweden, United States and United Kingdom. Matts Kågedal's co-authors include Mats O. Karlsson, Chunze Li, Sandhya Girish, Svante Nyberg, Zsolt Cselényi, Dan Lu, Divya Samineni, Christer Halldin, Jin Y. Jin and Andrew C. Hooker and has published in prestigious journals such as NeuroImage, Cancer Research and British Journal of Cancer.

In The Last Decade

Matts Kågedal

38 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matts Kågedal Sweden	13	182	165	113	77	49	38	517
Guy Meno‐Tetang United States	13	238 1.3×	150 0.9×	419 3.7×	78 1.0×	18 0.4×	21	1.2k
Diana Cao Australia	12	138 0.8×	142 0.9×	173 1.5×	60 0.8×	8 0.2×	32	649
Zangdong He United States	12	286 1.6×	153 0.9×	277 2.5×	36 0.5×	29 0.6×	23	637
Eugène Cox United States	12	182 1.0×	22 0.1×	154 1.4×	79 1.0×	33 0.7×	22	623
Kimberly Benson United States	8	209 1.1×	32 0.2×	184 1.6×	54 0.7×	14 0.3×	11	817
Marc Hattenberger Switzerland	7	139 0.8×	27 0.2×	195 1.7×	69 0.9×	13 0.3×	7	550
Marcus Schultze‐Mosgau Germany	13	83 0.5×	186 1.1×	130 1.2×	34 0.4×	8 0.2×	17	624
Aliénor Berges United Kingdom	14	311 1.7×	66 0.4×	538 4.8×	17 0.2×	26 0.5×	34	843
Shoichi Ohwada Japan	14	181 1.0×	66 0.4×	87 0.8×	19 0.2×	16 0.3×	20	447
Cinthia V. Pastuskovas United States	11	225 1.2×	218 1.3×	184 1.6×	36 0.5×	5 0.1×	17	584

Countries citing papers authored by Matts Kågedal

Since Specialization

Citations

This map shows the geographic impact of Matts Kågedal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matts Kågedal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matts Kågedal more than expected).

Fields of papers citing papers by Matts Kågedal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matts Kågedal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matts Kågedal. The network helps show where Matts Kågedal may publish in the future.

Co-authorship network of co-authors of Matts Kågedal

This figure shows the co-authorship network connecting the top 25 collaborators of Matts Kågedal. A scholar is included among the top collaborators of Matts Kågedal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matts Kågedal. Matts Kågedal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoshida, Kenta, et al.. (2024). Simulation‐based evaluation of personalized dosing approaches for anti‐FGFR/KLB bispecific antibody fazpilodemab. CPT Pharmacometrics & Systems Pharmacology. 13(4). 544–550. 4 indexed citations

Kågedal, Matts, Mauricio Maia, Tong Lu, et al.. (2023). Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age‐Related Macular Degeneration. The Journal of Clinical Pharmacology. 63(11). 1210–1220. 4 indexed citations

Bruno, René, Pascal Chanu, Matts Kågedal, et al.. (2023). Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models. British Journal of Cancer. 129(9). 1383–1388. 13 indexed citations

Lu, Tong, et al.. (2023). gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve. CPT Pharmacometrics & Systems Pharmacology. 13(3). 341–358. 2 indexed citations

Langenhorst, Jurgen, et al.. (2023). A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. Clinical and Translational Science. 16(11). 2310–2322. 3 indexed citations

Wykoff, Charles C., Peter A. Campochiaro, Dante J. Pieramici, et al.. (2022). Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration. Ophthalmology and Therapy. 11(5). 1705–1717. 8 indexed citations

Wang, Bei, Rong Deng, Stefanie Hennig, et al.. (2021). Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer Chemotherapy and Pharmacology. 88(3). 499–512. 11 indexed citations

Zhang, Wenhui, et al.. (2021). A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis. Journal of Pharmacokinetics and Pharmacodynamics. 49(2). 179–190. 2 indexed citations

Kirschbrown, Whitney P., Matts Kågedal, Bei Wang, et al.. (2019). Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer Chemotherapy and Pharmacology. 83(6). 1147–1158. 9 indexed citations

10.

Kågedal, Matts, Divya Samineni, William R. Gillespie, et al.. (2019). Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates. CPT Pharmacometrics & Systems Pharmacology. 8(8). 606–615. 12 indexed citations

11.

Kirschbrown, Whitney P., Chris Wynne, Matts Kågedal, et al.. (2018). Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study. The Journal of Clinical Pharmacology. 59(5). 702–716. 28 indexed citations

12.

Kågedal, Matts, Leonid Gibiansky, Jian Xu, et al.. (2017). Platform model describing pharmacokinetic properties of vc-MMAE antibody–drug conjugates. Journal of Pharmacokinetics and Pharmacodynamics. 44(6). 537–548. 9 indexed citations

13.

Kågedal, Matts, Mats O. Karlsson, & Andrew C. Hooker. (2015). Improved precision of exposure–response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment. Journal of Pharmacokinetics and Pharmacodynamics. 42(3). 211–224. 2 indexed citations

14.

Maringwa, John, Matts Kågedal, Ulrika Wählby Hamrén, et al.. (2014). Pharmacokinetic–pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA). The Journal of Clinical Pharmacology. 55(3). 328–335. 11 indexed citations

15.

Nyberg, Svante, Aurelija Jučaitė, Akihiro Takano, et al.. (2013). Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR. The International Journal of Neuropsychopharmacology. 16(10). 2235–2244. 26 indexed citations

16.

Kalliomäki, Jarkko, Frank Miller, Matts Kågedal, & Rolf Karlsten. (2012). Early phase drug development for treatment of chronic pain — Options for clinical trial and program design. Contemporary Clinical Trials. 33(4). 689–699. 8 indexed citations

17.

Kågedal, Matts, Zsolt Cselényi, Svante Nyberg, et al.. (2012). Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers. NeuroImage. 61(4). 849–856. 27 indexed citations

18.

Huledal, Gunilla, et al.. (2007). Effect of NXY-059, a novel neuroprotectant, on the pharmacokinetics of a single dose of digoxin in healthy subjects. Current Medical Research and Opinion. 23(7). 1531–1539. 1 indexed citations

19.

Bergström, Mats, Roger Yates, Anders Wall, et al.. (2006). Blood–Brain Barrier Penetration of Zolmitriptan—Modelling of Positron Emission Tomography Data. Journal of Pharmacokinetics and Pharmacodynamics. 33(1). 75–91. 29 indexed citations

20.

Kågedal, Matts, et al.. (2005). Modelling a Spontaneously Reported Side Effect by Use of a Markov Mixed-Effects Model. Journal of Pharmacokinetics and Pharmacodynamics. 32(2). 261–281. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact